Latest news

Debiopharm Diagnostics portfolio company Biocartis ships its first Idylla instrument

Debiopharm Group™’s innovative antibiotic Debio 1450 – developed from its proprietary plateform Fabiotics – Receives Qualified Infectious Disease Product (QIDP)…

Debiopharm Group™ and Nobelex Biotech start two collaborations on development of new antibiotics against N. gonorrhoeae and enteric species

Debiopharm Group™ and TCG Lifesciences Ltd. announce successful completion of first phase of research collaboration on discovery of novel antibiotics

Debiopharm Group™ Announces Initiation of a Phase I Study of Debio 1450, an IV/oral Potent Antibiotic Active Against Staphylococcal Infections

Debiopharm Group™ moves forward three of its oncology clinical programs and will present the recent progresses at the 50th American…

Orient EuroPharma and Debiopharm Group™ announce their partnership and the launch of Pamorelin LA in Singapore

Evotec and Debiopharm Group™ to collaborate on development of new treatment for cancer

Curis and Debiopharm Group™ Report Preclinical Data for Debio 0932 at AACR Annual Meeting 2014